ClinicalTrials.gg
RecruitingNCT07081503Updated Sep 10, 2026

Phase 1 Study of ADX-626 in Healthy Participants

A Phase 1 interventional study of ADX-626 and Placebo in Healthy Adult Participants, sponsored by ADARx Pharmaceuticals, Inc.. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by ADARx Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).

Read the detailed description

A Phase 1, first-in-human study to assess the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-626 compared with placebo in healthy participants.

02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

ADARx Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 to 45 years at the time of
  • Males or women of non- (WONCBP)
  • Willing to comply with all study requirements while participating
  • Suitable venous access for blood sampling.
  • Body weight ≥ 50 kg and a (BMI) ≤25 kg/m2
  • Normal laboratory results including liver enzymes, , count, and coagulation parameters
  • Willing to use acceptable methods if applicable

Key Exclusion Criteria:

  • Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer
  • History of bleeding or coagulation disorders, prior instances of major bleeding, or a family history of bleeding disorders.
  • Current infection
  • Participation in an interventional drug study within the last 90 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    ADX-626

    Drug: ADX-626

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugADX-626

    siRNA duplex oligonucleotide

  • DrugPlacebo

    Saline

06

What researchers measure

Primary outcomes

  1. Safety of ADX-626 in Healthy Participants

    Incidence, relationship and severity of adverse events and serious adverse events

    Time frame: Day 1 to Day 365

Secondary outcomes

  1. Pharmacokinetics (PK) of ADX-626 - Maximum Concentration

    Cmax

    Time frame: Day 1 to Day 29

  2. Pharmacokinetics (PK) of ADX-626 - Time to Maximum Concentration

    Tmax

    Time frame: Day 1 to Day 29

  3. Pharmacokinetics (PK) of ADX-626 - Exposure

    Area Under the Curve (AUC)

    Time frame: Day 1 to Day 29

  4. Pharmacodynamics (PD) of ADX-626 - Factor XI

    Change from baseline in Factor XI measurements

    Time frame: Day 1 to Day 365

  5. Pharmacodynamics (PD) of ADX-626 - Blood Clotting Time

    Change from baseline in Activated Partial Thromboplastin Time (aPTT)

    Time frame: Day 1 to Day 365

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 23, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Jan 22, 2027
CompletionEst.
Jun 30, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07081503
Lead sponsor
ADARx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Aug 12, 2025
Primary completion
Jan 22, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Nali Castillo
Contact
info@adarx.com
877-232-7974
Arezoo Mirad, MD
study director · ADARx Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion